AGEN · Agenus
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $8.45
Note written ·
Price against the kill line
20.4% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $8.45, on record since 11 November 2026. The shares are down 5.9% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $8.45, a level the shares last exceeded in the run to their September high, which would show the shares leading the S&P 500. First-patient dosing in ROBBIN ahead of the first-quarter 2027 guidance would also show the call is wrong.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 31.5
- Revenue, change on a year (%)
- +4.1
- Gross margin (%)
- 100.0
- Operating margin (%)
- 36.2
- Free cash flow, four quarters ($M)
- −104
- Net cash, cash less debt ($M)
- 51.8
- Price to earnings (×)
- 9.9
- Enterprise value to sales (×)
- 1.9
All filed numbers
What Agenus reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 31.5 | +4.1 | 100.0 | 36.2 |
| first filed | 34.5 | +34.4 | 100.0 | 32.7 |
| first filed | 33.7 | +40.2 | 100.0 | 44.6 |
| first filed | 34.2 | +27.5 | 100.0 | 42.1 |
| first filed | 30.2 | +20.4 | 97.9 | −15.0 |
| first filed | 25.7 | +9.3 | 99.1 | −65.0 |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: 30.8 | 2.7 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +153.4 |
| Operating cash flow ($M) | −104 |
| Capital spending ($M) | 0.0 |
| Free cash flow ($M) | −104 |
| Cash and short-term investments ($M) | 86.9 |
| Debt ($M) long-term debt plus short-term borrowings | 35.1 |
| Net cash, cash less debt ($M) | 51.8 |
| Deferred revenue ($M) 0.0% on a year | 1.1 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 17.1 |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | −105 |
| Market value ($M) | 305 |
| Enterprise value, market value plus net debt ($M) | 253 |
| Enterprise value to sales (×) | 1.9 |
| Enterprise value to operating income (×) | 4.8 |
| Price to earnings (×) | 9.9 |
| Price to book value (×) | Not meaningful |
| Free-cash-flow yield (%) | −34.1 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 15.5% of shares outstanding sold short, 6.5 days of average trading to cover, +2.7% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $0 |
The thesis
Agenus is more likely to lag the S&P 500 over the next three months. The shares closed at $6.87 on 12 November 2026, and the company has no pivotal milestone before first-patient dosing in its ROBBIN Phase 3 trial, guided for the first quarter of 2027, which settles whether the funded plan stays on schedule.
The 5 November 2026 third-quarter report answered the funding question for now. Cash, cash equivalents and short-term investments were $86.9 million on 30 September 2026, against $18.7 million on 30 June 2026, and the company says the upfront proceeds fund operations through the third quarter of 2027.
ROBBIN is an approximately 850-patient trial of botensilimab plus balstilimab before surgery in Stage II/III microsatellite-stable (MSS) colon cancer. Its primary endpoint is event-free survival. The company says site qualification and start-up are under way in North America, Europe, South America and Asia (Agenus third-quarter release, 5 November 2026).
The warrants from the July 2026 placement tie further cash to trial milestones. Series A (strike $4.02) is tied to 60 patients enrolled, guided for the second quarter of 2027. Series B (strike $5.03) is tied to an interim pathologic response read, guided for the fourth quarter of 2027. Both strikes sit below the 12 November 2026 close.
The shares have already absorbed the funding, the Nature Medicine publication and the survival data. They closed at $7.22 on 11 November 2026 and fell to $6.87 on 12 November 2026, below their 50-day average and 6.1% lower than the close of $7.32 on 14 August 2026.
Bullish and bearish views on Agenus Inc.
The bull case on Agenus Inc. (AGEN), in brief: cash is reported and funds the start-up. The bear case: reported profit is largely non-cash.
Bull case
- Cash is reported and funds the start-up. Cash was $86.9 million on 30 September 2026, up from $18.7 million three months earlier, after the placement of about $85 million upfront led by Commodore Capital (Agenus third-quarter release, 5 November 2026; placement release, 13 July 2026). Agenus says this covers ROBBIN initiation, regulatory work and operations through the third quarter of 2027.
- Phase 2 data exist in MSS colon cancer. The NEST and UNICORN pre-surgery studies reported pathologic complete response in roughly 30% of MSS colon cancer patients (Agenus third-quarter release, 5 November 2026). UNICORN was published in Nature Medicine on 2 November 2026.
- Deep responses in dMMR disease. The NEOASIS cohort of 18 mismatch-repair-deficient (dMMR) colon cancer patients had 72% pathologic complete response and 83% major pathologic response after six weeks of treatment (Agenus ESMO release, 25 October 2026).
- Long-term survival is reported. Long-term C-800-01 data showed 33% three-year overall survival in refractory MSS metastatic colorectal cancer (Agenus third-quarter release, 5 November 2026; SITC release, 6 November 2026).
- A broker target sits far above the price. B. Riley Securities reiterated Buy and raised its price target to $16 on 9 November 2026, after the third-quarter report.
Bear case
- Reported profit is largely non-cash. Third-quarter revenue was $31.5 million (third quarter of 2025: $30.2 million), of which $25.5 million was non-cash royalty revenue and $6.0 million was pre-commercial product revenue. Operating income was $11.4 million and net income $2.8 million (Agenus third-quarter release, 5 November 2026).
- Warrant exercise adds share supply. Series A warrants cover 21,144,277 shares and Series B warrants cover 33,797,214 shares (placement release, 13 July 2026). Agenus had 45,161,916 shares outstanding on 8 September 2026 (Form S-3, filed 11 September 2026). Series A warrants expire 30 days after Agenus discloses 60 patients dosed.
- Runway past 2027 depends on trial pace. Without warrant cash, upfront funding ends in the third quarter of 2027, and the Series A trigger is guided for the second quarter of 2027.
- Good news has not lifted the shares. The close of $6.87 on 12 November 2026 is below the 50-day average and well under the 52-week intraday high of $10.31 set on 30 September 2026, after the Nature Medicine publication, the ESMO data and the SITC survival data.
- Population gap. NEOASIS tested dMMR disease, and the 33% survival figure comes from late-line metastatic patients. ROBBIN enrols MSS patients before surgery, where the roughly 30% response rate comes from Phase 2 studies.
- A second Phase 3 was dropped. As of 13 July 2026 Agenus no longer financially supports BATTMAN in late-line metastatic MSS colorectal cancer, which concentrates the company on ROBBIN.
Price setup
The shares closed at $6.87 on 12 November 2026. The 50-day average is $7.40 and the 200-day average is $5.09, both adjusted and as of that close. The shares sit below the first and above the second. The 3-month change is −6.1%.
Recent closes were $6.44 on 5 November 2026, $7.15 on 6 November 2026 and 9 November 2026, $7.02 on 10 November 2026 and $7.22 on 11 November 2026. The 52-week intraday high is $10.31 (30 September 2026), and the 52-week closing low is $2.77 (5 February 2026). The last close is 33.4% below the quoted high.
Both warrant strikes, $4.02 and $5.03, are below the price, so the warrants are in the money. The only insider transaction itemised in SEC filings is a Form 4 filed 2 October 2026 reporting a grant of 4,443 shares to director Thomas L. Harrison at $6.89 on 1 October 2026. Two more Form 4 filings since 15 August 2026 are not itemised. No earnings report falls inside the next 30 days.
Catalysts ahead
- ~16 November 2026 (est.): Quarterly 13F filing deadline for holdings at 30 September 2026. Shows whether investors in the July 2026 placement changed their Agenus holdings.
- ~March 2027 (est.): ROBBIN Phase 3 first-patient dosing (first quarter of 2027 guidance). Confirms the funded plan is on schedule; a slip would weaken the timeline the financing was raised to support.
- ~June 2027 (est.): Target of 60 patients enrolled in ROBBIN (second quarter of 2027 guidance). Starts the 30-day expiry clock on Series A warrants and brings the first warrant cash.
- ~December 2027 (est.): Interim pathologic response assessment of the first 100 ROBBIN patients (fourth quarter of 2027 guidance). First read of ROBBIN's pre-surgery response in MSS patients and the Series B warrant milestone.
What would change the view
A daily close above $8.45, a level the shares last exceeded in the run to their September high, which would show the shares leading the S&P 500. First-patient dosing in ROBBIN ahead of the first-quarter 2027 guidance would also show the call is wrong.
What it trades with
The shares trade with small-cap biotechnology and immuno-oncology sentiment, and with the investors who hold the July placement. No correlation figures are published here. The ESMO, Nature Medicine and SITC releases of late October and early November moved the shares less than the financing news of 13 July 2026, so company-specific trial timing carries more weight than the sector at present.
The evidence, claim by claim (8)
- Cash, cash equivalents and short-term investments were $86.9 million on 30 September 2026, up from $18.7 million on 30 June 2026; upfront proceeds fund operations through the third quarter of 2027. Agenus third-quarter 2026 results release, 5 November 2026 · as of
- Third-quarter 2026 revenue was $31.5 million (third quarter of 2025: $30.2 million): $25.5 million non-cash royalty revenue and $6.0 million pre-commercial product revenue; operating income $11.4 million; net income $2.8 million. Agenus third-quarter 2026 results release, 5 November 2026 · as of
- ROBBIN (about 850 patients, event-free survival endpoint) is guided for first patient in the first quarter of 2027, 60 patients in the second quarter of 2027 and an interim pathologic response assessment of 100 patients in the fourth quarter of 2027. Agenus third-quarter 2026 results release, 5 November 2026 · as of
- NEST and UNICORN Phase 2 pre-surgery studies reported roughly 30% pathologic complete response in MSS colon cancer; UNICORN was published in Nature Medicine. Agenus third-quarter 2026 results release, 5 November 2026; Agenus announcement, 2 November 2026 · as of
- NEOASIS dMMR colon cohort (18 patients): 72% pathologic complete response and 83% major pathologic response after six weeks of treatment. Agenus ESMO 2026 release, 25 October 2026 · as of
- Long-term C-800-01 data showed 33% three-year overall survival in refractory MSS metastatic colorectal cancer. Agenus third-quarter 2026 results release, 5 November 2026 · as of
- Private placement of about $85 million upfront, up to $340 million with warrants; Series A warrants on 21,144,277 shares at $4.02 and Series B on 33,797,214 shares at $5.03. Agenus press release and Form 8-K, 13 July 2026 · as of
- B. Riley Securities reiterated Buy on Agenus and raised its price target to $16. B. Riley Securities rating headline, 9 November 2026 · as of
Sources
Related · shared themes
ABBV
AbbVie
AbbVie's Skyrizi and Rinvoq, each up more than 22% in the 30 October 2026 third-quarter report, keep lifting guidance and analyst targets…
GMAB
Genmab A/S
Genmab's own cancer drugs are becoming a second engine beside its DARZALEX royalty, with three launches targeted for 2027. ASH data on 14…
MRK
Merck
Merck's newer drugs and under-the-skin Keytruda are carrying its growth after raised 2026 guidance on 29 October 2026; the early-February…
REGN
Regeneron Pharmaceuticals
Regeneron's shares are modestly more likely than not to beat the S&P 500 because it now keeps its full Dupixent profit share, with EYLEA HD…
See also · stocks to watch